<DOC>
	<DOCNO>NCT00184717</DOCNO>
	<brief_summary>This study conduct Japan . The aim trial ass efficacy safety somatropin child bear small gestational age ( SGA ) Japan . In main period , subject receive either active treatment 104 week ( two dose regimen ) treatment 52 week follow extension period subject receive active treatment 104 week ( two year ) continue treatment 156 week ( three year ) subject receive treatment 52 week ( one year ) randomise receive two dose regimen 208 week ( four year ) . In total , subject participate trial 260 week ( five year ) . Main period register internally Novo Nordisk GHLIQUID-1516 extension period register GHLIQUID-1517 .</brief_summary>
	<brief_title>Growth Hormone Treatment Children Born Small Gestational Age ( SGA )</brief_title>
	<detailed_description />
	<criteria>For MAIN period ( GHLIQUID1516 ) : Born small gestational age ( SGA ) birth weight birth length 10th percentile gestational age , additional either birth length equal 2.0 standard deviation score ( SDS ) birth weight equal 2.0 SDS gestational age Growth failure height 2.0 SDS chronological age ( CA ) Normal growth hormone ( GH ) production , define peak GH level &gt; 10 ng/mL one GH provocation test For EXTENSION period ( GHLIQUID1517 ) : Subjects complete main period Chronological age ( CA ) boys least 4 year , maximum 11 year Chronological age ( CA ) girls least 4 year , maximum 10 year Subjects diabetes mellitus Subjects suffer malignancy Several medical condition</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>